1. AN IMPROVED BENEFIT‐RISK PROFILE OF DUVELISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WHO RECEIVED 2 OR MORE PRIOR THERAPIES. (12th June 2019) Authors: Flinn, I.W.; Davids, M.S.; Hillmen, P.; Montillo, M.; Delgado, J.; Kuss, B.J.; Tam, C.S.; Jäger, U.; Ghia, P.; Stilgenbauer, S.; Lustgarten, S.; Weaver, D.T.; Youssoufian, H.; Cymbalista, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY MARGINAL ZONE LYMPHOMA: DATA FROM THE PHASE 2 DYNAMO TRIAL. (12th June 2019) Authors: Jacobsen, E.; Ďuraš, J.; Ardeshna, K.; Cherry, M.; Offner, F.; Mayer, J.; Bijou, F.; Tani, M.; Musuraca, G.; Merli, M.; Marasca, R.; Weaver, D.T.; Lustgarten, S.; Youssoufian, H.; Zinzani, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 400 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Comparative efficacy of tyrosine kinase inhibitor treatments in the third-line setting, for chronic-phase chronic myelogenous leukemia after failure of second-generation tyrosine kinase inhibitors. Issue 1 (January 2015) Authors: Lipton, J.H.; Bryden, P.; Sidhu, M.K.; Huang, H.; McGarry, L.J.; Lustgarten, S.; Mealing, S.; Woods, B.; Whelan, J.; Hawkins, N. Journal: Leukemia research Issue: Volume 39:Issue 1(2015:Jan.) Page Start: 58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Duvelisib, an oral dual PI3K‐δ, γ inhibitor, efficacy and safety in patients with relapsed or refractory (RR) peripheral T‐cell lymphoma: rationale for the phase 2 PRIMO trial. (12th June 2019) Authors: Horwitz, S.M.; Foss, F.M.; Porcu, P.; Moskowitz, A.; Mehta‐Shah, N.; Jacobsen, E.; Khodadoust, M.S.; Kim, Y.H.; Weinstock, D.; Lustgarten, S.; Baglio, M.; Youssoufian, H.; Brammer, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 65 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY CLL/SLL IN THE DUO TRIAL. (12th June 2019) Authors: Ghia, P.; Flinn, I.W.; Lamanna, N.; Montillo, M.; Illés, Á.; Etienne, G.; Delgado, J.; Kuss, B.J.; Tam, C.S.; Offner, F.; Bosch, F.; Davids, M.S.; Jäger, U.; Cymbalista, F.; Weaver, D.T.; Lustgarten, S.; Youssoufian, H.; Stilgenbauer, S. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PATTERNS OF DUVELISIB‐INDUCED LYMPHOCYTOSIS IN PATIENTS WITH R/R CLL OR SLL INCLUDING THOSE WITH HIGH‐RISK FACTORS TREATED IN THE DUO TRIAL. (12th June 2019) Authors: Barrientos, J.; Flinn, I.; Davids, M.S.; Cashen, A.; Chiorazzi, N.; Chen, S.; Hidy, S.; Pachter, J.; Lustgarten, S.; Weaver, D.T.; Brown, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 216 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗